Recruiting

Duobrii & Biologics

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Code:

NCT04119102

Conditions

Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Duobrii

Study Details

Brief summary:

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Conditions

Psoriasis

Study ID

NCT04119102

Start date

Oct 14, 2019

Status verified date

Apr, 2020

Completion date

Sep 1, 2020

Anticipated

Primary completion date

Aug 1, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Psoriasis affecting 2%-10% BSA
4. Patient is being treated with biologic therapy for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures

Exclusion Criteria:

1. Psoriasis affecting ˂2% or >10% BSA
2. Patient not receiving a biologic agent, or receiving biologic agent <24weeks
3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
4. Has previously used DUOBRII

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Open Label Duobrii

Duobrii QD

Interventions

Duobrii

duobrii applied daily for 4 weeks followed by every other day for 4 weeks.

Primary outcome measure

  • Body surface area improvement [ Time Frame: 8 weeks ]

Central Contacts and Locations

Locations

Psoriasis Treatment Center of Central New Jersey

Recruiting

East Windsor, New Jersey, United States, 08520

Contacts

Principal Investigator:

Jerry Bagel, MD

More Information

Sponsor

Psoriasis Treatment Center of Central New Jersey

Last update posted

Apr 30, 2020

Last verified

Apr, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Psoriasis Treatment Center of Central New Jersey on 2020-04-30.